WESPAC Advisors SoCal LLC Buys Shares of 28,288 Novo Nordisk A/S (NYSE:NVO)

WESPAC Advisors SoCal LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 28,288 shares of the company's stock, valued at approximately $3,368,000.

Other large investors also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Gilliland Jeter Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. Halpern Financial Inc. boosted its position in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company's stock valued at $30,000 after purchasing an additional 113 shares during the period. Finally, Abound Wealth Management grew its stake in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company's stock worth $31,000 after buying an additional 157 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NVO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $144.50.

Novo Nordisk A/S Stock Performance

NVO traded down $3.58 during trading on Friday, hitting $101.74. The stock had a trading volume of 8,076,248 shares, compared to its average volume of 5,863,428. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market capitalization of $456.56 billion, a P/E ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company's 50-day moving average price is $118.58 and its 200 day moving average price is $129.59.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.